Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (311-320 of 385) with videos related to

Pageof 39
Sort By:
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Nature Genetics|June 14, 2022
Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programsMalgorzata Gozdecka, Eshwar Meduri, Milena Mazan, et al.
Nature Genetics|May 9, 2018
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programsMalgorzata Gozdecka, Eshwar Meduri, Milena Mazan, et al.
Nature Cancer|October 31, 2023
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemiaClaudia Bruedigam, Amy H Porter, Axia Song, et al.
Leukemia|August 30, 2023
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphomaFranziska Briest, Daniel Noerenberg, Cornelius Hennch, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|June 2, 2011
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cellsFlorian Kuchenbauer, Sarah M Mah, Michael Heuser, et al.
Nature Genetics|November 26, 2024
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotypeAino-Maija Leppä, Karen Grimes, Hyobin Jeong, et al.
Journal of Hematology & Oncology|May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysisNico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Pageof 39

Showing results (311-320 of 385) with videos related to

Sort By:
Pageof 39
Hemasphere|July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product UseVeit Bücklein, Ariel Perez, Kai Rejeski, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Nature Genetics|June 14, 2022
Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programsMalgorzata Gozdecka, Eshwar Meduri, Milena Mazan, et al.
Nature Genetics|May 9, 2018
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programsMalgorzata Gozdecka, Eshwar Meduri, Milena Mazan, et al.
Nature Cancer|October 31, 2023
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemiaClaudia Bruedigam, Amy H Porter, Axia Song, et al.
Leukemia|August 30, 2023
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphomaFranziska Briest, Daniel Noerenberg, Cornelius Hennch, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|June 2, 2011
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cellsFlorian Kuchenbauer, Sarah M Mah, Michael Heuser, et al.
Nature Genetics|November 26, 2024
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotypeAino-Maija Leppä, Karen Grimes, Hyobin Jeong, et al.
Journal of Hematology & Oncology|May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysisNico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Pageof 39